Insider Analysis From L.E.K. Consulting On The Private Health Insurance Market In China: Business As Usual Or Breakthrough Imminent?
This article was originally published in PharmAsia News
Executive Summary
In the midst of China’s massive healthcare reforms, including focus on expanding health insurance coverage, one area has not received much attention from policy makers and market participants until recently – the private health insurance market.
You may also be interested in...
China's Pilot DRG Reimbursement Systems Indicate Substantial Changes To Hospital Prescription Habits
SHANGHAI - China is experimenting with pilot reimbursement programs that rely on diagnosis related groups (DRG) in cities across the country, looking for ways to reduce medical expenses
China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen
SHANGHAI - China recently lifted a ban on foreign investment in medical institutes to support its $124 billion healthcare reforms and the establishment of wholly foreign-owned hospitals and clinics. The move by the Chinese government is being read as a signal that China may open more of the country's healthcare industry to foreign investment
Insider Analysis From L.E.K Consulting On Expanding In China’s Medtech Market (Part 3 of 3)
Already the fourth largest medtech market in the world, China’s $17 billion medical device industry is expected to more than double in size in the next five years, paving the way for incredible opportunities for growth. Identifying where the opportunities lie, navigating the tendering process and determining the right sales and distribution models are essential for multinational device makers.